Pseudohypoparathyroidism medical therapy: Difference between revisions
Jump to navigation
Jump to search
Irfan Dotani (talk | contribs) No edit summary |
Mazia Fatima (talk | contribs) |
||
| (18 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Pseudohypoparathyroidism}} | {{Pseudohypoparathyroidism}} | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}}{{Mazia}} | ||
{{ | |||
==Overview== | ==Overview== | ||
The mainstay of treatment for pseudohypoparathyroidism is oral [[calcium]] and 1alpha-hydroxylated vitamin D analogues, such as [[calcitriol]]. Other forms of Vitamin D cannot be used as [[parathyroid]] hormone resistance in the [[proximal tubule]] decreases the efficiency of production of 1,25(OH)2 vitamin D from 25-hydroxyvitamin D.Intravenous calcium is recommended for all patients who develop severe symptomatic [[hypocalcemia]]. | |||
==Medical Therapy== | ==Medical Therapy== | ||
*The mainstay of treatment for pseudohypoparathyroidism is oral [[calcium]] and 1alpha-hydroxylated vitamin D metabolites, such as [[calcitriol]] <ref name="pmid26943720">{{cite journal |vauthors=Clarke BL, Brown EM, Collins MT, Jüppner H, Lakatos P, Levine MA, Mannstadt MM, Bilezikian JP, Romanischen AF, Thakker RV |title=Epidemiology and Diagnosis of Hypoparathyroidism |journal=J. Clin. Endocrinol. Metab. |volume=101 |issue=6 |pages=2284–99 |year=2016 |pmid=26943720 |pmc=5393595 |doi=10.1210/jc.2015-3908 |url=}}</ref> | |||
*Other forms of [[Vitamin D]] cannot be used as [[parathyroid]] hormone resistance in the [[proximal tubule]] decreases the production of 1,25(OH)2 vitamin D from 25-hydroxyvitamin D.Intravenous [[calcium]] is recommended for all patients who develop severe symptomatic [[hypocalcemia]] | |||
*The majority of cases of pseudohypoparathyroidism are self-limited and require only supportive care | |||
* The goal of therapy is to: | |||
** Serum [[calcium]] within the normal range to prevent [[hypercalciuria]] | |||
** Maintain [[parathyroid]] hormone levels within reference range which helps prevent bone remodeling and [[hyperparathyroid]] bone disease | |||
**Intravenous [[calcium]] is recommended for all patients who develop severe symptomatic [[hypocalcemia]] | |||
*'''Adult''' | |||
**Preferred regimen (1):elemental [[calcium]] (either [[calcium chloride]] or [[calcium gluconate]]) 100 mg of over 10 to 20 minute | |||
**An additional dose of 100 mg/hr of [[elemental calcium]] can be infused if symptoms do not resolve, with close monitoring of [[calcium]] levels | |||
**[[Cardiac]] monitoring may help to guide therapy as rapid infusion of [[calcium]] can cause [[cardiac]] conduction defects | |||
**Preferred regimen (2):[[Parenteral|Parentera]]<nowiki/>l formulations available are [[calcium chloride]] and [[calcium gluconate|calcium]] [[calcium gluconate|gluconate]] 100 mg of over 10 to 20 minute | |||
*** <nowiki/>10% [[calcium chloride]] a 10-mL ampule contains 360 mg of [[elemental calcium]] | |||
*** 10% [[calcium gluconate]] 10-mL ampule contains 93 mg of elemental [[calcium]] | |||
*'''''For [[neonates]], [[infants]], and [[children]]''''' | |||
**Preferred regimen (1):10% [[calcium gluconate]] 0.5-1 mL/kg of administered over 5 minutes | |||
{| class="wikitable" | |||
! colspan="2" |Adverse drug reactions | |||
|- | |||
|[[Calcium chloride]] | |||
| | |||
* Rapid [[Intravenous injection]] may cause the patient to complain of [[tingling]] sensations, a [[calcium]] taste | |||
* Injections of [[calcium chloride]] are accompanied by [[Vasodilation|peripheral vasodilation]] as well as a local “burning” sensation, and there may be a moderate fall in [[blood pressure]] | |||
|- | |||
|[[Calcium gluconate]] | |||
| | |||
* Patients may complain of tingling sensations, a sense of heat waves and a [[calcium]] or chalky taste following the [[intravenous]] administration of [[calcium gluconate]] | |||
* Rapid [[intravenous injection]] of [[calcium]] salts may cause [[vasodilation]], decreased [[blood pressure]], [[bradycardia]], [[cardiac arrhythmias]], [[syncope]] and [[cardiac arrest]]. Use in digitalized patients may precipitate [[arrhythmias]] | |||
* Local [[necrosis]] and [[abscess]] formation may occur with [[intramuscular injection]] | |||
|} | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Endocrinology]] | [[Category:Endocrinology]] | ||
Latest revision as of 19:27, 17 October 2017
|
Pseudohypoparathyroidism Microchapters |
|
Differentiating Pseudohypoparathyroidism from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Pseudohypoparathyroidism medical therapy On the Web |
|
American Roentgen Ray Society Images of Pseudohypoparathyroidism medical therapy |
|
Risk calculators and risk factors for Pseudohypoparathyroidism medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mazia Fatima, MBBS [2]
Overview
The mainstay of treatment for pseudohypoparathyroidism is oral calcium and 1alpha-hydroxylated vitamin D analogues, such as calcitriol. Other forms of Vitamin D cannot be used as parathyroid hormone resistance in the proximal tubule decreases the efficiency of production of 1,25(OH)2 vitamin D from 25-hydroxyvitamin D.Intravenous calcium is recommended for all patients who develop severe symptomatic hypocalcemia.
Medical Therapy
- The mainstay of treatment for pseudohypoparathyroidism is oral calcium and 1alpha-hydroxylated vitamin D metabolites, such as calcitriol [1]
- Other forms of Vitamin D cannot be used as parathyroid hormone resistance in the proximal tubule decreases the production of 1,25(OH)2 vitamin D from 25-hydroxyvitamin D.Intravenous calcium is recommended for all patients who develop severe symptomatic hypocalcemia
- The majority of cases of pseudohypoparathyroidism are self-limited and require only supportive care
- The goal of therapy is to:
- Serum calcium within the normal range to prevent hypercalciuria
- Maintain parathyroid hormone levels within reference range which helps prevent bone remodeling and hyperparathyroid bone disease
- Intravenous calcium is recommended for all patients who develop severe symptomatic hypocalcemia
- Adult
- Preferred regimen (1):elemental calcium (either calcium chloride or calcium gluconate) 100 mg of over 10 to 20 minute
- An additional dose of 100 mg/hr of elemental calcium can be infused if symptoms do not resolve, with close monitoring of calcium levels
- Cardiac monitoring may help to guide therapy as rapid infusion of calcium can cause cardiac conduction defects
- Preferred regimen (2):Parenteral formulations available are calcium chloride and calcium gluconate 100 mg of over 10 to 20 minute
- 10% calcium chloride a 10-mL ampule contains 360 mg of elemental calcium
- 10% calcium gluconate 10-mL ampule contains 93 mg of elemental calcium
- For neonates, infants, and children
- Preferred regimen (1):10% calcium gluconate 0.5-1 mL/kg of administered over 5 minutes
| Adverse drug reactions | |
|---|---|
| Calcium chloride |
|
| Calcium gluconate |
|
References
- ↑ Clarke BL, Brown EM, Collins MT, Jüppner H, Lakatos P, Levine MA, Mannstadt MM, Bilezikian JP, Romanischen AF, Thakker RV (2016). "Epidemiology and Diagnosis of Hypoparathyroidism". J. Clin. Endocrinol. Metab. 101 (6): 2284–99. doi:10.1210/jc.2015-3908. PMC 5393595. PMID 26943720.